2025年,CXO行业似乎已经走出了低谷,其中药明康德一季度利润增速为89.06%、康龙化成增速为32.54%、凯莱英增速为15.83%。在整个行业复苏的背景下,明星公司泰格医药却显得有点显眼,继2024年业绩下滑79.99%后,2025年一季度业绩同比降29.61%。要知道,作为中国临床CRO领域的龙头,泰格医药曾参与了国内60%已上市一类新药研发,连续多年保持市场份额领先。如今在行业复苏浪潮中...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.